3 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2041. from the record
Of the 7 now held by other companies, 7 name Jiangsu Aosaikang Pharmaceutical Co. Ltd. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2041
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Sep 2041 · High confidence
Also notable
Ends Jan 2043 · High confidence
Novel IL-15 Prodrugs and Methods of Use Thereof
US 11,845,801
The most cited patent in this portfolio, cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
Novel Masked Cytokines and Methods of Use Thereof
US 12,600,762
Granted 2026. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Oct 2037 · High confidence
Cited by 8 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037.
now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Also notable
Ends no later than Mar 2040 · Medium confidence
Granted 2022. Computed term ends 2040. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 19, 2027The maintenance fee for Novel IL-15 Prodrugs and Methods of Use Thereof (US 11,845,801) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
Recent changes
- Oct 26Assignment recorded on 6 records: Askgene Pharma, Inc. to Jiangsu Aosaikang Pharmaceutical Co., Ltd. Recorded Oct 26, 2026, executed Sep 28, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76509, frame 890.
- Oct 22Assignment recorded on 2 patents: Askgene Pharma, Inc. to Jiangsu Aosaikang Pharmaceutical Co., Ltd. Recorded Oct 22, 2026, executed Sep 28, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76471, frame 538.
- 1 of the patents on this record was granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Novel Masked Cytokines and Methods of Use Thereof | 1 in force | to Jan 2043 |
| IL-21 Prodrugs and Methods of Use Thereof | 1 in force | to Sep 2042 |
| Novel IL-15 Prodrugs and Methods of Use Thereof | 1 in force | to Sep 2041 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,845,801 | Novel IL-15 Prodrugs and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,459,980 | IL-21 Prodrugs and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,600,762 | Novel Masked Cytokines and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 7 patents in force now held by others · 2 patents ended · 7 applications pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed